Investigational Drug Information for Miravirsen
✉ Email this page to a colleague
What is the drug development status for Miravirsen?
Miravirsen is an investigational drug.
There have been 5 clinical trials for Miravirsen.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2012.
The most common disease conditions in clinical trials are Hepatitis A, Hepatitis, and Hepatitis, Chronic. The leading clinical trial sponsors are Santaris Pharma A/S and [disabled in preview].
Summary for Miravirsen
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 47 |
| Japanese Patent Applications | 28 |
| Clinical Trial Progress | Phase 2 (2012-11-01) |
| Vendors | 5 |
Recent Clinical Trials for Miravirsen
| Title | Sponsor | Phase |
|---|---|---|
| Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C | Santaris Pharma A/S | Phase 2 |
| Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection | Santaris Pharma A/S | Phase 2 |
| Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C | Santaris Pharma A/S | Phase 2 |
Clinical Trial Summary for Miravirsen
Top disease conditions for Miravirsen
Top clinical trial sponsors for Miravirsen
US Patents for Miravirsen
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
